STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Fesoterodine

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled
- Not Controlled

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

• The substance is not similar to any of those included in the Schedules to the CDSA.

Prepared by: ___________________________ Date: Nov 19th 2010
Evelyn C Soo

Verified by: ___________________________ Date: ___________
Marianne Tang

Approved by: ___________________________ Date: ___________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: “third party information removed as per agreement with applicant”.
Drug Status Report

**Drug:** Fesoterodine

**Drug Name Status:** Fesoterodine is the common name.

**Chemical Name:** 2-((1R)-3-(bis(1-methylethyl)amino)1-phenylpropyl)-4-(hydroxymethyl)phenyl, 2-methyl-3-propanoic acid

**Chemical structure:**

![Chemical structure of Fesoterodine]

**Molecular Formula:** C_{26}H_{37}NO_{3}

**Pharmacological class / Application:** Antimuscarinic

**CAS-RN:** 286930-02-7

**International status:**

US: The substance is not listed specifically in the CSA and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: Fesoterodine is a drug used for the treatment of overactive bladder\(^1\). The drug is not currently listed in the CDSA and is not similar in structure to any of those included in the Schedules to the CDSA.

**Recommendation:** Fesoterodine is not included in the schedules to the CDSA and is not a controlled substance.

**Date:** November 19\(^{th}\) 2010

---

\(^{1}\)Kraus, SR. *et al.* (2010) Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder, *Urology, in press.*